B
KNSA icon

Braidwell’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Braidwell’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Sell
183,822
-88,700
-33% -$4.6M 0.43% 65
2026
Q1 		$13.1M Sell
272,522
-41,301
-13% -$1.83M 0.44% 67
2025
Q4 		$12.9M Sell
313,823
-329,357
-51% -$13.2M 0.41% 63
2025
Q3 		$25M Sell
643,180
-459,400
-42% -$14.9M 0.74% 39
2025
Q2 		$30.5M Sell
1,102,580
-860,329
-44% -$21.9M 1.04% 33
2025
Q1 		$43.6M Sell
1,962,909
-1,489,538
-43% -$30.7M 1.53% 27
2024
Q4 		$68.3M Buy
3,452,447
+557,934
+19% +$12.7M 2.02% 16
2024
Q3 		$72.3M Buy
2,894,513
+836,210
+41% +$20.4M 2.05% 18
2024
Q2 		$38.4M Buy
2,058,303
+665,587
+48% +$12.5M 1.21% 36
2024
Q1 		$27.5M Buy
+1,392,716
New +$27.2M 0.89% 41

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Braidwell's KNSA Position: Q2 2026 in Review

Braidwell reduced its Kiniksa Pharmaceuticals (KNSA) stake by 33% in Q2 2026, selling an estimated $4.6M and leaving 183,822 shares worth $11.8M. The position accounts for 0.43% of the portfolio, ranked #65.

Braidwell first reported a position in KNSA in Q1 2024 and has held it in 10 quarters since. The position peaked at $72.3M in Q3 2024. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Braidwell held 183,822 shares of Kiniksa Pharmaceuticals worth $11.8M as of Q2 2026.
  • Braidwell sold 88,700 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $4.6M.
  • Kiniksa Pharmaceuticals made up 0.43% of Braidwell's portfolio in Q2 2026, its #65 holding.
  • Braidwell first reported a position in Kiniksa Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Braidwell's Kiniksa Pharmaceuticals position peaked at $72.3M in Q3 2024.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.